The rs1024611 Regulatory Region Polymorphism Is Associated with CCL2 Allelic Expression Imbalance

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Pham, Minh Hieu T ^a,b   Bonello, Gregory B ^a,b   Castiblanco, John ^a,b   Le, Tuan ^a,b   Sigala, Jose ^a,b   He, Weijing ^a,b   Mummidi, Srinivas ^a,b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1;

3' UNTRANSLATED REGION; ALLELE; ALLELIC IMBALANCE; ARTICLE; CCL2 GENE; COHORT ANALYSIS; DNA POLYMORPHISM; GENE; GENE CONSTRUCT; GENE EXPRESSION; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; QUANTITATIVE ANALYSIS; REGULATORY SEQUENCE; REPORTER GENE; RNA SYNTHESIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE;

ALLELES; ALLELIC IMBALANCE; ASTROCYTES; BRAIN; CELL LINE, TRANSFORMED; CHEMOKINE CCL2; CHROMOSOME MAPPING; EPIGENESIS, GENETIC; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FREQUENCY; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; POLYMORPHISM, SINGLE NUCLEOTIDE; REGULATORY SEQUENCES, NUCLEIC ACID; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869228769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049498     Document Type: Article

References (96)

1. Deshmane SL, Kremlev S, Amini S, Sawaya BE, (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29: 313-326.
2. Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL, (2009) Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol 41: 998-1001.
3. Yadav A, Saini V, Arora S, (2010) MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 411: 1570-1579.
4. Charo IF, Ransohoff RM, (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-621.
5. Dhillon NK, Williams R, Callen S, Zien C, Narayan O, et al. (2008) Roles of MCP-1 in development of HIV-dementia. Front Biosci 13: 3913-3918.
6. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J, (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7: 327-340.
7. Iwamoto T, Okamoto H, Toyama Y, Momohara S, (2008) Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. Febs J 275: 4448-4455.
8. Donath MY, Shoelson SE, (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11: 98-107.
9. Gonzalez-Scarano F, Martin-Garcia J, (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5: 69-81.
10. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, et al. (2002) HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A 99: 13795-13800.
11. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, et al. (2005) CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 112: 1113-1120.
12. Cho ML, Kim JY, Ko HJ, Kim YH, Kim WU, et al. (2004) The MCP-1 promoter-2518 polymorphism in Behcet's disease: correlation between allele types, MCP-1 production and clinical symptoms among Korean patients. Autoimmunity 37: 77-80.
13. Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, et al. (2004) MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging 25: 1169-1173.
14. Karrer S, Bosserhoff AK, Weiderer P, Distler O, Landthaler M, et al. (2005) The-2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 124: 92-98.
15. Wang L, Yang L, Gao L, Gao TW, Li W, et al. (2008) A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with psoriasis. Int J Immunogenet 35: 45-49.
16. Rovin BH, Lu L, Saxena R, (1999) A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259: 344-348.
17. Tabara Y, Kohara K, Yamamoto Y, Igase M, Nakura J, et al. (2003) Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima-media thickness. Hypertens Res 26: 677-683.
18. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, et al. (2003) A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125: 1085-1093.
19. Berrahmoune H, Herbeth B, Lamont JV, Fitzgerald PS, Visvikis-Siest S, (2007) Association between TNF and IL-1 bloc polymorphisms and plasma MCP-1 concentration. Atherosclerosis 192: 348-353.
20. Schnabel RB, Baumert J, Barbalic M, Dupuis J, Ellinor PT, et al. (2010) Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 115: 5289-5299.
21. Letendre S, Marquie-Beck J, Singh KK, de Almeida S, Zimmerman J, et al. (2004) The monocyte chemotactic protein-1-2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J Neuroimmunol 157: 193-196.
22. Joven J, Coll B, Tous M, Ferre N, Alonso-Villaverde C, et al. (2006) The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis. Clin Chim Acta 368: 114-119.
23. Kim HL, Lee DS, Yang SH, Lim CS, Chung JH, et al. (2002) The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis 40: 1146-1152.
24. Zietz B, Buchler C, Herfarth H, Muller-Ladner U, Spiegel D, et al. (2005) Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein-1 that are not influenced by the-2518 A->G promoter polymorphism. Diabetes Obes Metab 7: 570-578.
25. van Wijk DF, van Leuven SI, Sandhu MS, Tanck MW, Hutten BA, et al. (2010) Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease. Arterioscler Thromb Vasc Biol 30: 1460-1466.
26. Melzer D, Perry JR, Hernandez D, Corsi AM, Stevens K, et al. (2008) A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 4: e1000072.
27. Alonso-Villaverde C, Coll B, Parra S, Montero M, Calvo N, et al. (2004) Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 110: 2204-2209.
28. Flores-Villanueva PO, Ruiz-Morales JA, Song CH, Flores LM, Jo EK, et al. (2005) A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis. J Exp Med 202: 1649-1658.
29. Mummidi S, Bonello GB, Ahuja SK (2009) Confirmation of differential binding of Interferon Regulatory Factor-1 (IRF-1) to the functional and HIV disease-influencing-2578 A/G polymorphism in CCL2. Genes Immun 10: 197-198; author reply 199.
30. Wright EK Jr, Page SH, Barber SA, Clements JE, (2008) Prep1/Pbx2 complexes regulate CCL2 expression through the-2578 guanine polymorphism. Genes Immun 9: 419-430.
31. Page SH, Wright EK Jr, Gama L, Clements JE, (2011) Regulation of CCL2 expression by an upstream TALE homeodomain protein-binding site that synergizes with the site created by the A-2578G SNP. PLoS One 6: e22052.
32. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW, (2002) Allelic variation in human gene expression. Science 297: 1143.
33. Kurreeman FA, Schonkeren JJ, Heijmans BT, Toes RE, Huizinga TW, (2004) Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. Hum Mol Genet 13: 1755-1762.
34. Wang D, Sadee W, (2006) Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). Aaps J 8: E515-520.
35. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, et al. (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467: 52-58.
36. Intemann CD, Thye T, Forster B, Owusu-Dabo E, Gyapong J, et al. (2011) MCP1 haplotypes associated with protection from pulmonary tuberculosis. BMC Genet 12: 34.
37. Wang H, Elbein SC, (2007) Detection of allelic imbalance in gene expression using pyrosequencing. Methods Mol Biol 373: 157-176.
38. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, et al. (2009) Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 325: 1246-1250.
39. Nica AC, Parts L, Glass D, Nisbet J, Barrett A, et al. (2011) The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet 7: e1002003.
40. Ragin AB, Wu Y, Ochs R, Scheidegger R, Cohen BA, et al. (2010) Biomarkers of neurological status in HIV infection: a 3-year study. Proteomics Clin Appl 4: 295-303.
41. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, et al. (2010) Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A 107: 21931-21936.
42. Abraham S, Sweet T, Sawaya BE, Rappaport J, Khalili K, et al. (2005) Cooperative interaction of C/EBP beta and Tat modulates MCP-1 gene transcription in astrocytes. J Neuroimmunol 160: 219-227.
43. Lim SP, Garzino-Demo A, (2000) The human immunodeficiency virus type 1 Tat protein up-regulates the promoter activity of the beta-chemokine monocyte chemoattractant protein 1 in the human astrocytoma cell line U-87 MG: role of SP-1, AP-1, and NF-kappaB consensus sites. J Virol 74: 1632-1640.
44. Iwai N, Kajimoto K, Kokubo Y, Okayama A, Miyazaki S, et al. (2006) Assessment of genetic effects of polymorphisms in the MCP-1 gene on serum MCP-1 levels and myocardial infarction in Japanese. Circ J 70: 805-809.
45. Johnson AD, Zhang Y, Papp AC, Pinsonneault JK, Lim JE, et al. (2008) Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics 18: 781-791.
46. Marsh CB, Wewers MD, Tan LC, Rovin BH, (1997) Fc(gamma) receptor cross-linking induces peripheral blood mononuclear cell monocyte chemoattractant protein-1 expression: role of lymphocyte Fc(gamma)RIII. J Immunol 158: 1078-1084.
47. Nyquist PA, Winkler CA, McKenzie LM, Yanek LR, Becker LC, et al. (2009) Single nucleotide polymorphisms in monocyte chemoattractant protein-1 and its receptor act synergistically to increase the risk of carotid atherosclerosis. Cerebrovasc Dis 28: 124-130.
48. Cirulli ET, Goldstein DB, (2007) In vitro assays fail to predict in vivo effects of regulatory polymorphisms. Hum Mol Genet 16: 1931-1939.
49. Bonello GB, Pham MH, Begum K, Sigala J, Sataranatarajan K, et al. (2011) An evolutionarily conserved TNF-alpha-responsive enhancer in the far upstream region of human CCL2 locus influences its gene expression. J Immunol 186: 7025-7038.
50. Teferedegne B, Green MR, Guo Z, Boss JM, (2006) Mechanism of action of a distal NF-kappaB-dependent enhancer. Mol Cell Biol 26: 5759-5770.
51. Nyquist P, Zhang J, De Graba TJ, (2010) The-928 G/C and-362 G/C single-nucleotide polymorphisms in the promoter of MCP-1: Increased transcriptional activity and novel binding sites. Cerebrovasc Dis 29: 242-247.
52. Zhou ZH, Chaturvedi P, Han YL, Aras S, Li YS, et al. (1998) IFN-gamma induction of the human monocyte chemoattractant protein (hMCP)-1 gene in astrocytoma cells: functional interaction between an IFN-gamma-activated site and a GC-rich element. J Immunol 160: 3908-3916.
53. Buckland PR, (2006) The importance and identification of regulatory polymorphisms and their mechanisms of action. Biochim Biophys Acta 1762: 17-28.
54. Buijtels PC, van de Sande WW, Parkinson S, Petit PL, van der Sande MA, et al. (2008) Polymorphism in CC-chemokine ligand 2 associated with tuberculosis in Zambia. Int J Tuberc Lung Dis 12: 1485-1488.
55. Ganachari M, Ruiz-Morales JA, Gomez de la Torre Pretell JC, Dinh J, Granados J, et al. (2010) Joint effect of MCP-1 genotype GG and MMP-1 genotype 2G/2G increases the likelihood of developing pulmonary tuberculosis in BCG-vaccinated individuals. PLoS One 5: e8881.
56. Alagarasu K, Selvaraj P, Swaminathan S, Raghavan S, Narendran G, et al. (2009) CCR2, MCP-1, SDF-1a & DC-SIGN gene polymorphisms in HIV-1 infected patients with & without tuberculosis. Indian J Med Res 130: 444-450.
57. Chu SF, Tam CM, Wong HS, Kam KM, Lau YL, et al. (2007) Association between RANTES functional polymorphisms and tuberculosis in Hong Kong Chinese. Genes Immun 8: 475-479.
58. Moller M, Nebel A, Valentonyte R, van Helden PD, Schreiber S, et al. (2009) Investigation of chromosome 17 candidate genes in susceptibility to TB in a South African population. Tuberculosis (Edinb) 89: 189-194.
59. Thye T, Nejentsev S, Intemann CD, Browne EN, Chinbuah MA, et al. (2009) MCP-1 promoter variant-362C associated with protection from pulmonary tuberculosis in Ghana, West Africa. Hum Mol Genet 18: 381-388.
60. Feng WX, Mokrousov I, Wang BB, Nelson H, Jiao WW,et al. Tag SNP polymorphism of CCL2 and its role in clinical tuberculosis in Han Chinese pediatric population. PLoS One 6: e14652.
61. Carter KW, McCaskie PA, Palmer LJ, (2006) JLIN: a java based linkage disequilibrium plotter. BMC Bioinformatics 7: 60.
62. Excoffier L, Laval G, Schneider S, (2005) Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 1: 47-50.
63. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996-1006.
64. Rosenbloom KR, Dreszer TR, Pheasant M, Barber GP, Meyer LR, et al. (2010) ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res 38: D620-625.
65. Zhou X, Maricque B, Xie M, Li D, Sundaram V, et al. (2011) The Human Epigenome Browser at Washington University. Nat Methods 8: 989-990.
66. Brenner D, Labreuche J, Touboul PJ, Schmidt-Petersen K, Poirier O, et al. (2006) Cytokine polymorphisms associated with carotid intima-media thickness in stroke patients. Stroke 37: 1691-1696.
67. Gonzalez-Enriquez GV, Rubio-Benitez MI, Garcia-Gallegos V, Portilla-de Buen E, Troyo-Sanroman R, et al. (2008) Contribution of TNF-308A and CCL2-2518A to carotid intima-media thickness in obese mexican children and adolescents. Arch Med Res 39: 753-759.
68. Yuasa S, Maruyama T, Yamamoto Y, Hirose H, Kawai T, et al. (2009) MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes. Diabetes Res Clin Pract 86: 193-198.
69. Alioglu E, Turk U, Cam S, Abbasaliyev A, Tengiz I, et al. (2009) Polymorphisms of the methylenetetrahydrofolate reductase, vascular endothelial growth factor, endothelial nitric oxide synthase, monocyte chemoattractant protein-1 and apolipoprotein E genes are not associated with carotid intima-media thickness. Can J Cardiol 25: e1-5.
70. Kim MP, Wahl LM, Yanek LR, Becker DM, Becker LC, (2007) A monocyte chemoattractant protein-1 gene polymorphism is associated with occult ischemia in a high-risk asymptomatic population. Atherosclerosis 193: 366-372.
71. Bjarnadottir K, Eiriksdottir G, Aspelund T, Gudnason V, (2006) Examination of genetic effects of polymorphisms in the MCP-1 and CCR2 genes on MI in the Icelandic population. Atherosclerosis 188: 341-346.
72. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, et al. (2001) Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis 158: 233-239.
73. Cavestro GM, Zuppardo RA, Bertolini S, Sereni G, Frulloni L, et al. (2010) Connections between genetics and clinical data: Role of MCP-1, CFTR, and SPINK-1 in the setting of acute, acute recurrent, and chronic pancreatitis. Am J Gastroenterol 105: 199-206.
74. Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, et al. (2007) Monocyte chemoattractant protein-1: plasma concentrations and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 34: 740-746.
75. Aguilar F, Gonzalez-Escribano MF, Sanchez-Roman J, Nunez-Roldan A, (2001) MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens 58: 335-338.
76. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG, (2010) Functional monocyte chemoattractant protein-1 promoter-2518 polymorphism and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 37: 3421-3426.
77. Sanchez E, Sabio JM, Callejas JL, de Ramon E, Garcia-Portales R, et al. (2006) Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus. BMC Med Genet 7: 48.
78. Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, et al. (2004) Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 50: 1842-1849.
79. Malafronte P, Vieira JM Jr, Pereira AC, Krieger JE, Barros RT, et al. (2010) Association of the MCP-1-2518 A/G polymorphism and no association of its receptor CCR2-64 V/I polymorphism with lupus nephritis. J Rheumatol 37: 776-782.
80. Nakashima H, Akahoshi M, Shimizu S, Inoue Y, Miyake K, et al. (2004) Absence of association between the MCP-1 gene polymorphism and histological phenotype of lupus nephritis. Lupus 13: 165-167.
81. Szalai C, Kozma GT, Nagy A, Bojszko A, Krikovszky D, et al. (2001) Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 108: 375-381.
82. Chelbi H, Ghadiri A, Lacheb J, Ghandil P, Hamzaoui K, et al. (2008) A polymorphism in the CCL2 chemokine gene is associated with asthma risk: a case-control and a family study in Tunisia. Genes Immun 9: 575-581.
83. Yao TC, Wu KC, Chung HT, Shaw CK, Kuo ML, et al. (2004) MCP-1 gene regulatory region polymorphism in Chinese children with mild, moderate and near-fatal asthma. Allergy 59: 436-441.
84. Ahluwalia TS, Khullar M, Ahuja M, Kohli HS, Bhansali A, et al. (2009) Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 4: e5168.
85. Boger CA, Fischereder M, Deinzer M, Aslanidis C, Schmitz G, et al. (2005) RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 183: 121-129.
86. Kaur S, Panicker SR, James T, Sarma PS, Thankappan KR, et al. (2009) Association of monocyte chemoattractant protein-1-2518 polymorphism with metabolic syndrome in a South Indian cohort. Metab Syndr Relat Disord 7: 193-198.
87. Carulli MT, Spagnolo P, Fonseca C, Welsh KI, duBois RM, et al. (2008) Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosis. J Rheumatol 35: 839-844.
88. Radstake TR, Vonk MC, Dekkers M, Schijvenaars MM, Treppichio WL, et al. (2009) The-2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: results from a multicenter study of European Caucasian patients. Hum Immunol 70: 130-133.
89. Palmieri O, Latiano A, Salvatori E, Valvano MR, Bossa F, et al. (2010) The-A2518G polymorphism of monocyte chemoattractant protein-1 is associated with Crohn's disease. Am J Gastroenterol 105: 1586-1594.
90. Vilades C, Broch M, Plana M, Domingo P, Alonso-Villaverde C, et al. (2007) Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects. J Acquir Immune Defic Syndr 44: 132-138.
91. Pola R, Flex A, Gaetani E, Proia AS, Papaleo P, et al. (2004) Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer's disease in Italians. Exp Gerontol 39: 1249-1252.
92. Huerta C, Alvarez V, Mata IF, Coto E, Ribacoba R, et al. (2004) Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci Lett 370: 151-154.
93. Combarros O, Infante J, Llorca J, Berciano J, (2004) No evidence for association of the monocyte chemoattractant protein-1 (-2518) gene polymorphism and Alzheimer's disease. Neurosci Lett 360: 25-28.
94. Ghilardi G, Biondi ML, La Torre A, Battaglioli L, Scorza R, (2005) Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1)-2518 G allele. Clin Chem 51: 452-455.
95. Kozma GT, Falus A, Bojszko A, Krikovszky D, Szabo T, et al. (2002) Lack of association between atopic eczema/dermatitis syndrome and polymorphisms in the promoter region of RANTES and regulatory region of MCP-1. Allergy 57: 160-163.
96. Glas J, Torok HP, Tonenchi L, Schiemann U, Folwaczny C (2004) The-2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection. Gastroenterology 126: 1930-1931; author reply 1931-1932.